A detailed history of Strs Ohio transactions in Novavax Inc stock. As of the latest transaction made, Strs Ohio holds 26,100 shares of NVAX stock, worth $355,221. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,100
Previous 111,300 76.55%
Holding current value
$355,221
Previous $532,000 37.97%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 05, 2024

SELL
$3.89 - $20.97 $331,428 - $1.79 Million
-85,200 Reduced 76.55%
26,100 $330,000
Q1 2024

May 13, 2024

BUY
$3.76 - $6.02 $41,736 - $66,822
11,100 Added 11.08%
111,300 $532,000
Q4 2023

Jan 30, 2024

BUY
$4.8 - $7.67 $94,560 - $151,099
19,700 Added 24.47%
100,200 $480,000
Q3 2023

Oct 26, 2023

SELL
$6.81 - $9.74 $27,240 - $38,960
-4,000 Reduced 4.73%
80,500 $582,000
Q2 2023

Jul 31, 2023

BUY
$6.67 - $9.52 $563,615 - $804,440
84,500 New
84,500 $627,000
Q2 2022

Jul 25, 2022

SELL
$36.28 - $75.29 $156,004 - $323,747
-4,300 Closed
0 $0
Q1 2022

Apr 21, 2022

BUY
$69.73 - $142.9 $299,839 - $614,470
4,300 New
4,300 $316,000
Q4 2021

Jan 24, 2022

SELL
$134.56 - $217.97 $458,311 - $742,405
-3,406 Closed
0 $0
Q3 2021

Oct 22, 2021

BUY
$177.8 - $270.58 $605,586 - $921,595
3,406 New
3,406 $706,000
Q2 2021

Jul 26, 2021

SELL
$121.0 - $257.67 $1.71 Million - $3.63 Million
-14,100 Closed
0 $0
Q1 2021

Apr 23, 2021

BUY
$112.98 - $319.93 $248,556 - $703,846
2,200 Added 18.49%
14,100 $2.56 Million
Q4 2020

Jan 25, 2021

BUY
$78.74 - $139.5 $39,370 - $69,750
500 Added 4.39%
11,900 $1.33 Million
Q3 2020

Dec 14, 2020

BUY
$79.44 - $178.51 $238,320 - $535,530
3,000 Added 35.71%
11,400 $1.24 Million
Q2 2020

Jul 23, 2020

BUY
$13.86 - $83.61 $116,424 - $702,324
8,400 New
8,400 $700,000

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $1.06B
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Strs Ohio Portfolio

Follow Strs Ohio and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

News

Stay updated on Strs Ohio with notifications on news.